Multimodality treatment of patients with advanced ovarian carcinoma

Journal Article · Fri Oct 01 04:00:00 EDT 1982 · Int. J. Radiat. Oncol., Biol. Phys.; (United States)

DOI:https://doi.org/10.1016/0360-3016(82)90285-1· OSTI ID:5147529

Torres, J L.P. ^[1]; Bross, D S; Hernandez, E; Rosenshein, N; Klein, J L; Ettinger, D S; Leichner, P K; Order, S E

---

1. Johns Hopkins Hospital, Baltimore, MD

A multimodality treatment program has been applied to ovarian carcinoma at the Johns Hopkins Hospital since August 1975. Forty-nine patients were subdivided into 23 patients with maximally resected Stage III micrometastatic, and 26 patients with significant retained disease, 20 with Stage III macrometastatic and 6 with Stage IV. After initial pilot studies, those patients with minimally retained disease entered a randomized prospective study. Antiovarian antiserum was used in one arm of the study; in both study arms colloidal P-32, delayed split whole abdominal irradiation, and maintenance melphalan were used. For the 23 patients with micrometastatic disease the cumulative survival and survival without evidence of disease at four years is 78 and 34% respectively. Twenty-six patients with macrometastatic disease were treated with or without intraperitoneal antiserum and multiagent chemotherapy; their cumulative one year survival is 50%. The lack of significant toxicity of intraperitoneal antiovarian antiserum and the results of multimodality therapy indicate the feasibility of this therapeutic approach to further improve ovarian cancer therapy.

• OSTI ID: 5147529
• Journal Information: Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 8:10; ISSN IOBPD
• Country of Publication: United States
• Language: English

Related Subjects

550600 -- Medicine
550603* -- Medicine-- External Radiation in Therapy-- (1980-)
550604 -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ABDOMEN
ANTINEOPLASTIC DRUGS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
BODY AREAS
CARCINOMAS
CHEMOTHERAPY
DAYS LIVING RADIOISOTOPES
DISEASES
DRUGS
EXTERNAL IRRADIATION
FEMALE GENITALS
GONADS
IMMUNE SERUMS
IMMUNOTHERAPY
IRRADIATION
ISOTOPES
LIGHT NUCLEI
MEDICINE
METASTASES
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-ODD NUCLEI
ORGANS
OVARIES
PARTIAL BODY IRRADIATION
PATIENTS
PHOSPHORUS 32
PHOSPHORUS ISOTOPES
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
SURVIVAL TIME
THERAPY